| Type of support |
Approvals 2001-2022 (US$)(29 May 2018) |
Commitments 2001-2022 (US$)(29 May 2018) |
Disbursements 2000-2018 (US$)(29 May 2018) |
% Disbursed(29 May 2018) |
2002 |
2003 |
2004 |
2005 |
2006 |
2007 |
2008 |
2009 |
2010 |
2011 |
2012 |
2013 |
2014 |
2015 |
2016 |
2017 |
2018 |
2019 |
2020 |
2021 |
|---|
|
| Total |
$965,148,345 |
$1,231,168,031 |
$953,837,242 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Cash Support (CASHSUPP) |
$170,000 |
$195,000 |
$170,000 |
100% |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Civil Society Organisation support (CSO) |
$3,320,000 |
$3,320,000 |
$3,420,000 |
103% |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Cold Chain Equipment Optimisation Platform (CCEOP) |
$4,747,678 |
$20,875,664 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Health system strengthening (HSS 1) |
$76,493,935 |
$76,493,935 |
$76,493,935 |
100% |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Health system strengthening (HSS 2) |
$61,410,682 |
$61,410,682 |
$61,410,682 |
100% |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Health system strengthening (HSS 3) |
$34,540,000 |
$80,590,000 |
$34,540,000 |
100% |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| HPV (NVS) |
$12,659,500 |
$40,478,500 |
$4,649,580 |
37% |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| HPV Demo (NVS) |
$147,439 |
$147,439 |
$147,439 |
100% |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| HPV MAC (NVS) |
|
$50,803,000 |
|
N/A |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| HPV MAC - Op costs (OPC) |
|
$4,195,200 |
|
N/A |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Immunisation services support (ISS) |
$23,445,320 |
$23,445,320 |
$17,813,320 |
76% |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Injection Safety Devices (NVS) |
$2,276,655 |
$5,626,155 |
$2,737,506 |
120% |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Injection safety support (INS) |
$2,696,697 |
$2,696,697 |
$2,696,697 |
100% |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| IPV (NVS) |
$10,426,463 |
$10,426,463 |
$8,601,251 |
82% |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Measles 1st and 2nd dose (NVS) |
$714,500 |
$1,954,500 |
$799,488 |
112% |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Measles SIA (NVS) |
$8,458,031 |
$8,458,031 |
$8,458,031 |
100% |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Measles SIA - Operational costs (OPC) |
$15,098,453 |
$15,098,453 |
$15,075,741 |
100% |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Meningitis A - campaign (NVS) |
$43,030,647 |
$43,030,647 |
$44,310,479 |
103% |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Meningitis A - operational costs (OPC) |
$37,949,808 |
$37,949,808 |
$34,028,741 |
90% |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Penta (NVS) |
$236,504,887 |
$255,927,887 |
$235,828,690 |
100% |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Pneumo (NVS) |
$309,645,911 |
$380,731,411 |
$325,426,535 |
105% |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Rotavirus (NVS) |
$69,996,471 |
$95,897,971 |
$65,814,025 |
94% |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Vaccine Introduction Grant (VIG) |
$11,415,268 |
$11,415,268 |
$11,415,102 |
100% |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Red line on table indicates duration of support based on commitments.
Commitments: Multi-year programme budgets endorsed in principle by the Gavi Board. These become financial commitments upon approval each year for the following calendar year.
Approvals: Total Approved for funding
Download data for commitments, approvals & disbursements in XLS format